Skip to main content
Tejaswini Kulkarni, MD, Pulmonology, Birmingham, AL

Tejaswini Kulkarni MD

Pulmonology•Birmingham, AL

Critical Care Medicine, Interstitial Lung Diseases, Occupational & Environmental Lung Disease

Associate Professor Director, Interstitial Lung Disease Program

Join to view full profile

  • 1717 6th Ave SBirmingham, AL 35233

  • Phone+1 800-822-8816

Dr. Kulkarni is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Kulkarni's full profileAlready have an account?

Summary

  • Dr. Tejaswini Kulkarni is a pulmonologist based in Birmingham, AL, with subspecialties in Critical Care Medicine, Interstitial Lung Diseases, and Occupational & Environmental Lung Disease. She completed her fellowship in Pulmonary Disease and Critical Care Medicine at the University of Alabama Medical Center and her residency in Internal Medicine at Detroit Medical Center/Wayne State University. She is an Associate Professor at the University of Alabama Hospital and has expertise in interstitial lung diseases, particularly those associated with connective tissue diseases and idiopathic pulmonary fibrosis. Dr. Kulkarni has authored several publications in reputable journals on topics related to pulmonary fibrosis. Additionally, she is currently principal investigator/ co-investigator on clinical trials studying new therapeutics for pulmonary fibrosis.

Education & Training

  • University of Alabama Hospital (Birmingham)
    University of Alabama Hospital (Birmingham)Fellowship, Pulmonary Disease and Critical Care Medicine, 2013 - 2016
  • Detroit Medical Center/Wayne State University
    Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine, 2010 - 2013
  • Bangalore Medical College
    Bangalore Medical CollegeClass of 2008

Certifications & Licensure

  • AL State Medical License
    AL State Medical License 2013 - 2026
  • MI State Medical License
    MI State Medical License 2010 - 2013
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Critical Care Medicine
    American Board of Internal Medicine Critical Care Medicine
  • Pulmonary Disease
    American Board of Internal Medicine Pulmonary Disease

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2017
  • CMS Meaningful Use Stage 1 Certification PowerChart (Clinical), Cerner Corporation, 2017
  • CMS Meaningful Use Stage 1 Certification HealtheLife and PowerChart, Cerner Corporation, 2017

Clinical Trials

Publications & Presentations

PubMed

Authored Content

  • An Update in Progressive Pulmonary FibrosisOctober 2022

Press Mentions

  • PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated Group
    PureTech Presents New Phase 2b Analyses Demonstrating Consistent Safety and Efficacy of Deupirfenidone in Older Patients with Idiopathic Pulmonary Fibrosis (IPF), a Historically Undertreated GroupOctober 22nd, 2025
  • PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
    PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPFAugust 21st, 2025
  • PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPF
    PureTech Showcases Differentiated Development Strategy, Including New Patient Preference Insights, and Spotlights Phase 2b Data Positioning Deupirfenidone as a Potential New Standard of Care in IPFAugust 21st, 2025

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Tejaswini Kulkarni, Dr. Tejaswini Kulkarni, MD, Dr. T Kulkarni